Keros Therapeutics (KROS) Competitors $16.96 -0.07 (-0.41%) (As of 03:04 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KROS vs. MRUS, ACAD, TWST, VCEL, MOR, SWTX, KYMR, ZLAB, GMTX, and VERAShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), Vericel (VCEL), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Zai Lab (ZLAB), Gemini Therapeutics (GMTX), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Merus ACADIA Pharmaceuticals Twist Bioscience Vericel MorphoSys SpringWorks Therapeutics Kymera Therapeutics Zai Lab Gemini Therapeutics Vera Therapeutics Merus (NASDAQ:MRUS) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations. Which has more risk and volatility, MRUS or KROS? Merus has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Which has preferable valuation & earnings, MRUS or KROS? Keros Therapeutics has lower revenue, but higher earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$43.95M65.19-$154.94M-$3.95-10.59Keros Therapeutics$651K1,059.65-$152.99M-$5.21-3.27 Is MRUS or KROS more profitable? Merus has a net margin of -680.61% compared to Keros Therapeutics' net margin of -27,890.94%. Merus' return on equity of -38.89% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Keros Therapeutics -27,890.94%-41.74%-38.42% Do analysts rate MRUS or KROS? Merus currently has a consensus target price of $85.64, suggesting a potential upside of 104.63%. Keros Therapeutics has a consensus target price of $81.33, suggesting a potential upside of 377.59%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14Keros Therapeutics 0 Sell rating(s) 4 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the MarketBeat Community prefer MRUS or KROS? Merus received 296 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 70.37% of users gave Keros Therapeutics an outperform vote while only 67.11% of users gave Merus an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes35367.11% Underperform Votes17332.89% Keros TherapeuticsOutperform Votes5770.37% Underperform Votes2429.63% Does the media prefer MRUS or KROS? In the previous week, Keros Therapeutics had 11 more articles in the media than Merus. MarketBeat recorded 18 mentions for Keros Therapeutics and 7 mentions for Merus. Merus' average media sentiment score of 0.41 beat Keros Therapeutics' score of 0.10 indicating that Merus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Keros Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of MRUS or KROS? 96.1% of Merus shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 4.6% of Merus shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryMerus beats Keros Therapeutics on 11 of the 19 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$689.83M$6.59B$5.15B$9.08BDividend YieldN/A2.99%5.12%4.25%P/E Ratio-3.2710.5587.1117.18Price / Sales1,059.65196.061,116.56117.12Price / CashN/A57.1643.2337.85Price / Book1.545.094.794.78Net Income-$152.99M$151.83M$120.55M$225.60M7 Day Performance-12.31%-1.08%-1.49%-1.36%1 Month Performance-69.55%-4.57%13.65%0.20%1 Year Performance-55.43%8.80%28.61%15.30% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.3212 of 5 stars$16.96-0.4%$75.00+342.2%-55.4%$687.00M$651,000.00-3.26100Analyst ForecastGap DownMRUSMerus2.4462 of 5 stars$42.78-0.1%$85.64+100.2%+54.6%$2.93B$43.95M-10.8437ACADACADIA Pharmaceuticals3.8628 of 5 stars$17.50+1.4%$25.60+46.3%-46.3%$2.91B$726.44M22.13510TWSTTwist Bioscience2.7132 of 5 stars$48.86+2.9%$51.90+6.2%+30.4%$2.90B$312.97M-13.19990VCELVericel1.2652 of 5 stars$57.97+0.9%$59.71+3.0%+62.6%$2.86B$226.84M957.83300MORMorphoSys0.1216 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics1.8081 of 5 stars$38.21-0.2%$69.50+81.9%-0.1%$2.84B$5.45M-9.87305KYMRKymera Therapeutics2.2612 of 5 stars$43.73+3.8%$53.88+23.2%+58.2%$2.83B$87.56M-18.00170ZLABZai Lab1.7154 of 5 stars$26.05-1.1%$55.00+111.1%+5.6%$2.83B$355.75M-9.512,175GMTXGemini TherapeuticsN/A$64.89+1.0%N/A+10.7%$2.81BN/A-64.8930VERAVera Therapeutics3.6176 of 5 stars$44.38+0.7%$59.22+33.4%+168.8%$2.81BN/A-16.8840Insider TradePositive News Related Companies and Tools Related Companies Merus Alternatives ACADIA Pharmaceuticals Alternatives Twist Bioscience Alternatives Vericel Alternatives MorphoSys Alternatives SpringWorks Therapeutics Alternatives Kymera Therapeutics Alternatives Zai Lab Alternatives Gemini Therapeutics Alternatives Vera Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KROS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
